Today was a good example of the "market" vs "me"! The 'market' acted like a coiled-up spring ready to explode, which it did in late afternoon trading, ratcheting up over 500 points on the DJIA and 56 points on the S&P, seemingly reflecting what I mentioned in my piece above from Dec 7, a sense that the Fed's 'war plan' on inflation will meet with success.
And as long as tomorrow's CPI is close to inline, I'd expect more of the same. Add to that, any 'nod and a wink' from Powell on Wednesday as if to say regarding inflation, "I've got this!" and KaBOOM...up and away the market will go.
As for the fears of earnings disappointing in early '23? The market is quick to push that aside. Not me! I look at days like today as a way to sift through my holdings in search of 'overvalued' stocks with risk to the downside on any disappointment from overly confident expectations. Eli Lilly (LLY) is one such stock. Don't get me wrong...I love the company. Strong balance sheet with a terrific new product pipeline. In the past, that was the upshot on LLY. But now, ask anyone about LLY (even the JPMorgan urban legend style of asking one's shoe-shiner) and they'll tell you that LLY is all about Mounjaro! The diabetes drug is already a blockbuster, but more because even without FDA approval yet for the weight-loss indication, doctors are prescribing it with abandon, enough that LLY just announced a sort of triage distribution plan to limit availability to better ensure that diabetes patients, for whom the drug is currently approved, can get access. Taking a look at LLY's PE, at 55, it's meaningfully higher than its 5yr average and median. Further, it's PEG is in the low 30s, meaning that earnings growth has to nearly double for the current valuation to be justified. Now, it is possible that when/if the FDA approves Mounjaro for weight loss, that these earnings goals can be met. But it's also possible that demand will be so great that LLY will still have a hard time meeting up w/supply! Further, and I pray this is not the case, but beyond a drug investment's 'probability', there's also 'possibility', and in the case of relatively new drugs, it's not a too infrequent event that some unforeseen side-effect unearths itself especially after the drug is in more widespread use. Given all of that, I trimmed a long-held position in LLY today, and if it continues to run, I'll trim further, if not exit entirely.
As always, whatever I've written here both explicitly and implied is NOT meant to be advice in any way, just food for thought and discussion.
Comments welcome.